Vivos Inc

Vivos Inc has a capital structure with no long-term debt and a debt-to-equity ratio of 0.0, indicating a purely equity-funded operation. The company's liquidity position is characterized by a current ratio of 14.01, suggesting strong short-term liquidity relative to its liabilities. However, the company's operating cash flow is negative at -$2,057,740, and free cash flow is -$3,168,840, indicating a lack of cash generation from operations. Profitability metrics show significant underperformance relative to industry norms. The company's return on equity is -1.8461 and return on assets is -1.6417, both of which are negative and far below the typical positive returns expected in the Advanced Medical Equipment & Technology industry. These figures suggest that the company is not generating returns for shareholders or effectively utilizing its assets. The company's revenue is concentrated in a single product line, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the company's ability to offset losses in one area with gains in another. The absence of segment or geographic breakdown in the financial data further obscures the company's risk profile. Growth trajectory is constrained by the company's current financial position. With a revenue of $68,380 and a net loss of -$3,066,020, the company is not demonstrating revenue expansion or path to profitability. The outlook for the current fiscal year does not indicate a significant change in this trend, and there is no disclosed revenue growth in the historical data to suggest a reversal of the current financial trajectory. Risk factors include the company's negative operating and free cash flows, which could lead to liquidity constraints if not addressed. The risk assessment indicates low dilution risk, but the absence of immediate filing-based liquidity or dilution flags does not preclude the need for ongoing monitoring. The company's reliance on equity financing and lack of debt could also be a double-edged sword, as it may limit access to capital in the future. Recent events include the continued development and demonstration of the IsoPet Solutions for veterinary use, which serves as a platform to showcase the safety and therapeutic effectiveness of the company's technology. No recent filings or transcripts indicate significant changes in the company's strategic direction or financial status.